KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Revenue (2016 - 2025)

Historic Revenue for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $167.2 million.

  • NovoCure's Revenue rose 780.75% to $167.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.3 million, marking a year-over-year increase of 1116.96%. This contributed to the annual value of $605.2 million for FY2024, which is 1882.48% up from last year.
  • NovoCure's Revenue amounted to $167.2 million in Q3 2025, which was up 780.75% from $158.8 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Revenue ranged from a high of $167.2 million in Q3 2025 and a low of $122.2 million during Q1 2023
  • Its 5-year average for Revenue is $140.4 million, with a median of $134.7 million in 2021.
  • Its Revenue has fluctuated over the past 5 years, first soared by 3227.7% in 2021, then plummeted by 1117.07% in 2023.
  • NovoCure's Revenue (Quarter) stood at $133.2 million in 2021, then dropped by 3.59% to $128.4 million in 2022, then increased by 4.17% to $133.8 million in 2023, then grew by 20.54% to $161.3 million in 2024, then rose by 3.68% to $167.2 million in 2025.
  • Its Revenue stands at $167.2 million for Q3 2025, versus $158.8 million for Q2 2025 and $155.0 million for Q1 2025.